Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany: What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation?

Lisa V.E. Oostenbrink, Cornelia M. Jol-van der Zijde, Anja M. Jansen-Hoogendijk, Emma S. Pool, Astrid G.S. van Halteren, Dirk Jan A.R. Moes, Robbert G.M. Bredius, Alex B. Mohseny, Frans J.W. Smiers, Maarten J.D. van Tol, Marco W. Schilham, Arjan C. Lankester

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

3 Citaten (Scopus)

Samenvatting

Antithymocyte globulin (ATG) is a widely accepted part of the conditioning regimen applied in the setting of hematopoietic stem cell transplantation (HSCT) to prevent graft rejection and graft-versus-host disease. Although weight-based dosing of ATG has been introduced to optimize ATG dosing, substantial variance in clearance of active ATG, the actual lymphocyte binding component, remains a challenge. Therefore, further research regarding ATG pharmacokinetics and pharmacodynamics in different HSCT settings and in patients with different types of underlying diseases is required.

Originele taal-2Engels
Pagina's (van-tot)61-65
Aantal pagina's5
TijdschriftHematology/ Oncology and Stem Cell Therapy
Volume13
Nummer van het tijdschrift2
DOI's
StatusGepubliceerd - jun. 2020
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany: What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation?'. Samen vormen ze een unieke vingerafdruk.

Citeer dit